Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine), the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
US FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)
-
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca
-
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refracatory multiple myeloma
GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate
-
Middle school teachers get hands-on experience in STEM careers
Second annual emPowering STEM Classroom to Career Conference to take place in RTP March 25th
-
Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer
TESARO announced the presentation of data from the Phase 1/2 GARNET study evaluating dostarlimab
-
GSK sponsors GSK Science in the Summer™ with Morehead Planetarium
Morehead Planetarium & Science Center is partnering with GSK for the 11th year to present GSK Science in the Summer™
-
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies showing long-acting, injectable two-drug regimen of cabotegravir and rilpivirine has similar efficacy to daily, three-drug oral treatment in adults living with HIV-1 infection
ViiV Healthcare presents positive, 48-week data from two pivotal phase III studies
-
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
GSK receives a positive CHMP opinion for intravenous zanamivir for the treatment of complicated influenza
-
GSK Science in the Summer™ unveils 2019 curriculum
Free STEM program in partnership with The Franklin Institute to reach 26,000 students nationwide this year.
-
GSK delivers sales, earnings and cash flow growth in 2018
Total EPS 73.7p, +>100% AER, +>100% CER; Adjusted EPS 119.4p +7% AER, +12% CER
-
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialize M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers
GSK and Merck KGaA, Darmstadt, Germany today announced that they have entered into a global strategic alliance
-
GSK completes acquisition of TESARO, an oncology focused biopharmaceutical company
GSK announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company
-
GSK announces succession plan to appoint new Chairman
GSK announces that Sir Philip Hampton has informed the Board of his intention to step down as non-executive Chairman
-
Two positive phase III studies of tafenoquine for the radical cure of Plasmodium vivax malaria published in The New England Journal of Medicine
GSK today announced the publication of positive results from two phase III studies of single-dose tafenoquine
-
GlaxoSmithKline plc and Pfizer Inc to form new world-leading Consumer Healthcare Joint Venture
GSK has reached agreement with Pfizer Inc to combine their consumer health businesses into a new world-leading Joint Venture.
-
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
GSK to divest Horlicks and other Consumer Healthcare nutrition products to Unilever
-
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company
-
GSK employees celebrate Giving Tuesday with awards to local nonprofits
GSK employees celebrate Giving Tuesday with awards to local nonprofits
-
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval
Juluca (dolutegravir/rilpivirine), the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval
-
Access to Medicine Index 2018 media statement
Access to Medicine Index 2018 media statement
